PKO Investment Management Joint Stock Co Acquires 2,000 Shares of Illumina, Inc. (NASDAQ:ILMN)

PKO Investment Management Joint Stock Co boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 133.3% in the first quarter, Holdings Channel.com reports. The fund owned 3,500 shares of the life sciences company’s stock after buying an additional 2,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Illumina were worth $278,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fourth Dimension Wealth LLC bought a new position in shares of Illumina in the 4th quarter worth $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina in the fourth quarter valued at about $45,000. Assetmark Inc. lifted its stake in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares during the period. Lee Danner & Bass Inc. bought a new position in Illumina during the fourth quarter worth about $48,000. Finally, Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.9%

ILMN opened at $89.47 on Wednesday. The stock has a market capitalization of $14.16 billion, a P/E ratio of -14.74, a P/E/G ratio of 1.77 and a beta of 1.33. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm’s fifty day simple moving average is $79.75 and its 200 day simple moving average is $101.88.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.98 earnings per share. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra purchased 6,100 shares of Illumina stock in a transaction on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 0.17% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Guggenheim decreased their price objective on shares of Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a report on Friday, May 9th. Royal Bank Of Canada lowered their target price on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, April 8th. Canaccord Genuity Group increased their target price on shares of Illumina from $87.00 to $99.00 and gave the stock a “hold” rating in a report on Wednesday, June 11th. Finally, Robert W. Baird decreased their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.94.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.